GLP-1 drugs and steroid cycles: what bodybuilders get wrong

What's this video probably claiming?

Based on the hashtag mix of #steriods, #bulking, #cuttingshapes, and #ozempic alongside a "4 weeks cycle done" caption, this creator is almost certainly walking viewers through using semaglutide (Ozempic or a compounded equivalent) as part of a bodybuilding cutting cycle, likely stacked with anabolic steroids. The framing is probably something like: GLP-1 drugs help you stay lean while on cycle, or they counteract the appetite increases that some anabolic compounds cause. There may also be claims about preserving muscle during a cut or accelerating fat loss beyond what the steroids alone produce. Four weeks is also a suspiciously short window to draw meaningful conclusions about body composition changes, which is a red flag before we even get to the transcript.

What does the science actually show?

Semaglutide's weight loss evidence is real but comes from very different populations than competitive bodybuilders. The STEP 1 trial (Wilding et al., 2021, NEJM) showed 14.9% mean body weight reduction over 68 weeks at 2.4mg weekly in adults with obesity, not lean athletes. The drug works primarily by slowing gastric emptying and reducing appetite via GLP-1 receptor agonism in the hypothalamus. Critically, the STEP trials did not control for resistance training, and participants lost meaningful lean mass alongside fat. A 2022 analysis by Lundgren et al. in Obesity found that roughly 40% of weight lost on semaglutide was lean tissue in sedentary subjects, which is a number bodybuilders should find alarming. Whether resistance training substantially changes that ratio in the context of semaglutide use remains under-studied in controlled trials.

Where does the social media noise diverge from clinical reality?

The bodybuilding community has latched onto GLP-1 drugs as a cutting tool, but several assumptions don't hold up under scrutiny. First, four weeks is nowhere near enough time to assess real body composition outcomes with semaglutide. The drug takes 4 to 5 weeks just to approach steady-state plasma concentrations at escalating doses. Second, stacking semaglutide with anabolic steroids introduces pharmacological interactions that have essentially zero controlled trial data behind them. Anabolic steroids affect insulin sensitivity and lipid metabolism in ways that may alter how the body responds to GLP-1 receptor agonism, but nobody has studied this formally. Third, Ozempic is FDA-approved for type 2 diabetes at doses up to 2mg weekly, not for bodybuilding fat loss. Compounded semaglutide versions circulating in fitness communities vary widely in concentration and purity, and they are not equivalent to FDA-approved branded formulations.

What should you actually know?

If you are considering GLP-1 therapy for body composition, the first honest conversation is about what problem you are actually solving. Semaglutide is a legitimate, well-evidenced tool for people with obesity or type 2 diabetes. Its role in lean, resistance-trained athletes is speculative at best and potentially counterproductive at worst given the lean mass loss data. The steroid angle adds a layer of risk that no clinical guidance covers, because that combination has not been studied and the liability falls entirely on the person using it. Compounded semaglutide is not the same product as Ozempic or Wegovy regardless of what the vial says. Anyone telling you otherwise is not reading the FDA's own guidance. If you are on a regulated telehealth platform, a licensed provider can assess whether GLP-1 therapy is appropriate for your specific health profile without the anabolic stack noise in the background.